TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Bank of Montreal Can

Bank of Montreal Can lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 17.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,457 shares of the company’s stock after buying an additional 12,484 shares during the quarter. Bank of Montreal Can’s holdings in TransMedics Group were worth $5,141,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TMDX. National Bank of Canada FI boosted its position in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in TransMedics Group during the fourth quarter worth about $31,000. Hager Investment Management Services LLC acquired a new position in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC acquired a new stake in shares of TransMedics Group during the 4th quarter valued at approximately $40,000. Finally, AlphaQuest LLC acquired a new stake in shares of TransMedics Group during the 4th quarter valued at approximately $52,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 7.8 %

Shares of TMDX stock opened at $86.84 on Tuesday. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 92.38 and a beta of 2.14. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a 50-day moving average price of $71.19 and a 200 day moving average price of $80.67. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on TMDX shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.